ALLIANCES (AstraZeneca) (Details) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Alliances Statement [Line Items]
Number of agreements in alliance	3								3
Net product sales									$ 12,304,000,000	$ 13,654,000,000	$ 17,622,000,000
Alliance and other revenues									4,081,000,000	3,967,000,000	3,622,000,000
Total Revenues	4,441,000,000	4,065,000,000	4,048,000,000	3,831,000,000	4,191,000,000	3,736,000,000	4,443,000,000	5,251,000,000	16,385,000,000	17,621,000,000	21,244,000,000
The percentage of capital expenditures to be reimbursed by AstraZeneca	50.00%								50.00%
Deferred income from alliances included in liabilities related to assets held-for-sale	3,671,000,000								3,671,000,000
Deferred income	1,525,000,000				4,849,000,000				1,525,000,000	4,849,000,000
Number of months following the closing of the business sales transaction for when a manufacturing facility may be sold	18 months								18 months
Onglyza Kombiglyze [Member]
Alliances Statement [Line Items]
Total Revenues									877,000,000	709,000,000	473,000,000
Bydureon [Member]
Alliances Statement [Line Items]
Total Revenues									298,000,000	78,000,000
Byetta [Member]
Alliances Statement [Line Items]
Total Revenues									400,000,000	149,000,000
AstraZeneca [Member]
Alliances Statement [Line Items]
Net product sales									1,658,000,000	962,000,000	472,000,000
Alliance and other revenues									16,000,000	10,000,000	1,000,000
Total Revenues									1,674,000,000	972,000,000	473,000,000
Payments to/(from) alliance partner- Cost of products sold									(25,000,000)	(4,000,000)
Payments to/(from) alliance partner - Marketing, selling and administrative									(127,000,000)	(66,000,000)	(14,000,000)
Payments to/(from) alliance partner - Advertising and product promotion									(45,000,000)	(43,000,000)	(21,000,000)
Payments to/(from) alliance partner - Research and development									(86,000,000)	(25,000,000)	35,000,000
AstraZeneca [Member] | Amylin Acquisition [Member]
Alliances Statement [Line Items]
Payment made by an alliance partner to enter into an alliance agreement										3,600,000,000
Payment made by an alliance partner to establish equal governance rights over certain key strategic and financial decisions regarding the alliance									135,000,000
Useful life of property, plant and equipment									15 years 0 months 0 days
Provision for restructuring									(25,000,000)	(21,000,000)
AstraZeneca [Member] | Onglyza Kombiglyze [Member] | Upfront, milestone and other licensing payments [Member]
Alliances Statement [Line Items]
Total upfront, milestone and other licensing payments received to date	300,000,000								300,000,000
Deferred income from alliances included in liabilities related to assets held-for-sale	191,000,000								191,000,000
Deferred income					208,000,000					208,000,000
AstraZeneca [Member] | Amylin Related Products [Member]
Alliances Statement [Line Items]
Cost of products sold - Amortization of deferred income									(307,000,000)	(126,000,000)
AstraZeneca [Member] | Amylin Related Products [Member] | Upfront, milestone and other licensing payments [Member]
Alliances Statement [Line Items]
Upfront, milestone and other licensing payments received									135,000,000	3,547,000,000
Deferred income from alliances included in liabilities related to assets held-for-sale	3,288,000,000								3,288,000,000
Deferred income					3,423,000,000					3,423,000,000
AstraZeneca [Member] | Forxiga [Member] | Upfront, milestone and other licensing payments [Member]
Alliances Statement [Line Items]
Upfront, milestone and other licensing payments received									80,000,000		120,000,000
Total upfront, milestone and other licensing payments received to date	250,000,000								250,000,000
Deferred income from alliances included in liabilities related to assets held-for-sale	192,000,000								192,000,000
Deferred income					206,000,000					206,000,000
AstraZeneca [Member] | Onglyza Kombiglyze Forxiga [Member]
Alliances Statement [Line Items]
Cost of products sold - Profit sharing											207,000,000
Other (income)/expense - Amortization of deferred income									(31,000,000)	(38,000,000)	(38,000,000)
AstraZeneca [Member] | Onglyza Kombiglyze Forxiga And Amylin Related Products [Member]
Alliances Statement [Line Items]
Cost of products sold - Profit sharing									$ 673,000,000	$ 425,000,000
AstraZeneca [Member] | Bydureon [Member]
Alliances Statement [Line Items]
Useful life of intangible asset									13 years 0 months 0 days
AstraZeneca [Member] | Byetta [Member]
Alliances Statement [Line Items]
Useful life of intangible asset									7 years 0 months 0 days
AstraZeneca [Member] | Symlin [Member]
Alliances Statement [Line Items]
Useful life of intangible asset									9 years 0 months 0 days
AstraZeneca [Member] | Metreleptin [Member]
Alliances Statement [Line Items]
Useful life of intangible asset									12 years 0 months 0 days